- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Obesity biotech Zealand seeks partners to 'take therapies directly to the brain' | ||
| Fr | 2026 outlook: Biotech poised to outperform bear markets of '21-24, analyst says | ||
| Fr | Arcus halts Gilead-partnered TIGIT trials as biotech reworks R&D focus | ||
| Fr | Cycle seizes struggling Applied Tx, picking up rare disease biotech for pennies per share | ||
| Do | Rezolute's stock plunges 87% after hypoglycemia drug flunks pivotal phase 3 test | ||
| Do | Lilly's obesity triple threat smashes efficacy expectations in phase 3 but proves intolerable for some | ||
| Do | Moderna taps Nanexa to improve delivery of injectable therapies in back-loaded $500M pact | ||
| Do | Zealand pens $2.5B oral cardiometabolic collab with fresh-faced Chinese biotech | ||
| Do | GRI touts IPF safety edge, lung function gains amid cash crunch | ||
| Mi | Apple Tree Partners files for bankruptcy to keep cash flowing to portfolio biotechs | ||
| Mi | Sanofi, GSK ink preclinical pacts in quest for new autoimmune and cancer antibodies | ||
| Mi | Bleecker's big bang: Formation Bio unveils new subsidiary with $605M Lynk deal | ||
| Mi | Roche links oral SERD to 30% breast cancer risk reduction in phase 3 adjuvant trial | ||
| Mi | Chinese biotech led by AstraZeneca veteran reels in $108M for KRAS phase 3 plans | ||
| Di | Rainbows, pickleball and puppies: Inside the 'enduring activism' and 'cautious optimism' at ASH 2025 | ||
| Di | ASH: Exicure rebounds with phase 2 win, seeing 90% blood cell mobilization in myeloma | ||
| Di | Ose narrows focus to conserve cash at expense of wider pipeline | ||
| Di | Pfizer continues renewed obesity push with $150M upfront for Fosun Pharma unit's GLP-1 drug | ||
| Di | FDA steers cancer CAR-T developers toward randomized superiority trials in policy shift | ||
| Di | Novartis pens $1.7B immuno-dermatology pact with AI-enabled British biotech | ||
| Mo | ASH: Merck mulls future of polycythemia program while Takeda takes phase 3 victory lap | ||
| Mo | With weight loss windfall, Lilly looks to become 'backbone' of global innovation: exec | ||
| Mo | Dr. Reddy's pens $370M pact for rights to Immutep's phase 3-stage immunotherapy in certain markets | ||
| Mo | Dyne readies FDA push after DMD exon 51 med excels in trial | ||
| Mo | Wave, Structure stocks double on obesity data readouts |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .